Volume turns tests into profit as oncology scales
- Q2 2026 generated $5.5M in operating income with gross margins holding near 70.5 percent.
- Prenatal revenue hit $95.8M in Q2 2026, growing 56 percent from a year earlier.
- Oncology revenue grew 176 percent year over year to $13.7M in the second quarter.
- The company held over $10M in claims during Q2 while waiting for national payer codes.
- A new Epic Aura integration is expected to speed up adoption by large health systems.
The flywheel meets billing friction
BillionToOne is a diagnostic testing company where scale dictates success. As more doctors order its tests, more volume flows through its labs. That gives the company a stronger position when negotiating with insurers, which can raise the average selling price and lower claim denials.
Operating leverage is becoming visible. Q2 2026 generated $5.5M in GAAP operating income while gross margins held near 70.5 percent. Total test volume reached roughly 196,000 tests in the quarter. A new integration with Epic Aura gives the company a structural advantage for winning business from large health systems.
The bull case relies on prenatal testing funding the business while oncology becomes the next growth leg. Oncology revenue jumped 176 percent year over year to $13.7M in Q2 2026. Upcoming launches like NorthStar Origin and MTAP loss detection provide new reasons for doctors to order these tests.
The bear case centers on how much insurers control the cash. More than 90 percent of revenue comes from third-party payors. In Q2 2026, the company had to hold more than $10M in claims while waiting for national payor code implementation. If those claims are denied or delayed further, the profit story could stall.
Paid when insurers agree
BillionToOne performs molecular diagnostic tests ordered by doctors and other health providers. It usually bills the patient's insurance carrier, the patient, or both after delivering the test result.
The company runs on its single-molecule next-generation sequencing platform. In plain English, that is a lab method that counts tiny pieces of genetic material with high precision. The same core technology supports both prenatal testing and cancer testing.
The model depends on a payor flywheel. Higher test volume can help the company sign in-network contracts, which can improve payment rates and reduce denials. Management notes that having a large base of contracted U.S. lives helps convert test volume into actual cash.
This is also where the model can break. A test can be useful to doctors but still fail as a business if insurers say it is not medically necessary, dispute the billing code, or demand repayment after an audit.
Prenatal today, cancer tomorrow
UNITY
The core prenatal test line. It is a single-gene non-invasive prenatal test for recessive conditions, with the Fetal Antigen Screen expanding to 130 genes in August 2026.
Unity Aneuploidy
The frontline prenatal screen that management wants more patients to use.
Unity Confirm
A circulating fetal cell-based confirmation assay. Management expects little direct revenue from it, but sees it as a way to make Unity Aneuploidy stand out.
Northstar Select
A pan-cancer liquid biopsy used to help select therapy. The company is adding MTAP copy number loss detection in September 2026.
Northstar Response
Measures tumor burden and therapy response without a tissue biopsy. Medicare coverage is a key near-term catalyst.
NorthStar Origin
A methylation-based tissue of origin add-on launching in the second half of 2026 to deliver specialized diagnostic performance.
Still mostly prenatal
The mix below is estimated based on Q2 2026 revenue of $95.8M for prenatal and $13.7M for oncology. Third-party payor reimbursement remains the central concentration issue.
What could break
Payor reimbursement shock
High impact · Medium oddsBillionToOne depends on insurers and government payors for most of its cash. In Q2 2026, the company held over $10M in claims while waiting for national payer coding implementation. If payors deny claims or dispute codes, revenue and margins could fall.
Northstar Response coverage stalls
High impact · Medium oddsThe oncology story needs broader coverage for Northstar Response. Management anticipates MolDX Medicare coverage, supported by a new peer-reviewed study. If Medicare or large commercial payors hesitate, the oncology mix may stop rising.
Prenatal concentration stays too high
Medium impact · Medium oddsPrenatal tests still generate the vast majority of revenue. That makes the company less diversified than the Northstar growth story suggests. If prenatal growth slows before oncology scales, the company could lose the volume leverage that supports margins.
Growth strains lab operations
Medium impact · Medium oddsFast volume growth can stress lab capacity, billing teams, and quality control. The company signed a lease for a new 62,000 square foot oncology production lab in California expected by late 2027, which could weigh on margins during the transition.
In one breath
What does BillionToOne actually sell?
It sells molecular diagnostic tests, mainly prenatal tests and cancer blood tests. Doctors order the tests, the company runs them in its labs, and it bills insurance carriers or patients.
Why is insurance coverage so important for the company?
More than 90 percent of revenue comes from third-party payors. If insurers pay faster and deny fewer claims, growth can turn into profit. If they push back, the same test volume may be worth much less.
What is the biggest near-term catalyst?
Medicare coverage for Northstar Response is the key item to watch. Management hopes a new peer-reviewed study will support expected MolDX Medicare coverage.
